André Lieber
André Lieber is Academic Cofounder at HDT Bio and a contract Scientific Co-founder at Ensoma. He is also Professor at the University of Washington.
Seattle Startup HDT Bio Secures $1.8M U.S. Army Grant to Develop Broad-Spectrum Antiviral Nasal Spray by 2025
Seattle startup HDT Bio received a nearly $1.8 million U.S. Army grant to develop a nasal spray using proprietary RNA technology that targets a broad range of respiratory viruses, with clinical trials expected to begin in 2025. The spray aims to prevent virus replication and transmission and could be used by both military personnel and civilians.
Ensoma launches in Boston with $70M Series A to commercialize Engenious gene‑editing adenoviral vectors developed by Fred Hutch and UW researchers
Boston-based biotech spinout Ensoma launched, announcing a $70 million Series A to commercialize Engenious adenoviral vectors developed by Drs. Hans-Peter Kiem (Fred Hutch) and André Lieber (UW) that aim to deliver single‑injection gene therapies without stem cell harvest or chemotherapy.
Organizations
-
HDT Bio Scientific Co-Founder 2020–present · current
-
Ensoma Scientific Co-founder 2019–present · current
-
University of Washington Professor 1994–present · current